


Product Name : PRN1008
Cat. No. : PC-62583
CAS No. : 1575596-29-0
Molecular Formula : C₃₆H₄₀FN₉O₃
Molecular Weight : 665.774
Target : BTK
Solubility : 10 mM in DMSO



Biological Activity

Rilzabrutinib (PRN1008) is a potent, selective, covalent reversible **BTK** inhibitor with IC₅₀ of 1.3 nM.

PRN1008 displays highly selective when tested in a panel of 251 other kinases.

PRN1008 inhibits anti-IgM induces human B cell proliferation (10% serum) and B cell CD69 expression, with IC₅₀s of 5 nM and 123 nM, respectively.

Rilzabrutinib (PRN1008) demonstrates in vivo efficacy in rodent arthritis models, and clinical efficacy in canine pemphigus foliaceus.

Rilzabrutinib (PRN1008) is in phase 3 trials for pemphigus vulgaris and immune thrombocytopenia.

References

Smith PF, et al. *Br J Clin Pharmacol*. 2017 Nov;83(11):2367-2376.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com